Your browser is no longer supported. Please, upgrade your browser.
Settings
SESN Sesen Bio, Inc. daily Stock Chart
SESN [NASD]
Sesen Bio, Inc.
Index- P/E- EPS (ttm)-0.51 Insider Own6.56% Shs Outstand100.36M Perf Week1.74%
Market Cap117.42M Forward P/E- EPS next Y-0.54 Insider Trans- Shs Float96.98M Perf Month-3.31%
Income-36.20M PEG- EPS next Q-0.12 Inst Own32.70% Short Float3.69% Perf Quarter-40.61%
Sales- P/S- EPS this Y51.00% Inst Trans45.98% Short Ratio1.16 Perf Half Y44.04%
Book/sh0.19 P/B6.16 EPS next Y41.80% ROA-70.30% Target Price3.58 Perf Year-34.27%
Cash/sh0.65 P/C1.81 EPS next 5Y- ROE-220.50% 52W Range0.66 - 2.60 Perf YTD-17.61%
Dividend- P/FCF- EPS past 5Y49.20% ROI- 52W High-53.08% Beta0.79
Dividend %- Quick Ratio8.50 Sales past 5Y- Gross Margin- 52W Low84.60% ATR0.07
Employees17 Current Ratio8.50 Sales Q/Q- Oper. Margin- RSI (14)51.48 Volatility4.04% 6.25%
OptionableYes Debt/Eq0.00 EPS Q/Q-323.90% Profit Margin- Rel Volume0.40 Prev Close1.17
ShortableYes LT Debt/Eq0.00 EarningsAug 13 BMO Payout- Avg Volume3.08M Price1.22
Recom1.70 SMA205.29% SMA50-8.73% SMA200-3.09% Volume1,233,411 Change4.27%
Jun-11-19Upgrade H.C. Wainwright Neutral → Buy $3
Aug-08-19 04:01PM  Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer Business Wire
Aug-05-19 07:30AM  Sesen Bio Strengthens Leadership Team Business Wire
Jul-31-19 07:30AM  Sesen Bio to Present at the Canaccord Genuity 39th Annual Growth Conference Business Wire +7.42%
Jul-25-19 12:33PM  Introducing Sesen Bio (NASDAQ:SESN), The Stock That Tanked 89% Simply Wall St.
Jul-17-19 04:10PM  Sesen Bio Announces Retirement of Leslie L. Dan Business Wire
Jun-25-19 08:37AM  Penny Stocks to Buy Using Technical Analysis for June 2019 Investopedia
Jun-22-19 02:35PM  Edited Transcript of SESN earnings conference call or presentation 13-May-19 12:00pm GMT Thomson Reuters StreetEvents
Jun-21-19 08:42AM  Implied Volatility Surging for Sesen Bio (SESN) Stock Options Zacks
Jun-19-19 08:00AM  Sesen Bio Announces Pricing of Public Offering of Common Stock and Warrants Business Wire -19.57%
07:51AM  The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut Benzinga
Jun-18-19 04:17PM  Sesen Bio Announces Proposed Public Offering of Common Stock and Warrants Business Wire
Jun-10-19 07:00AM  Sesen Bio Announces Successful Pre-BLA Meeting with FDA for Vicinium® Business Wire -18.10%
Jun-07-19 07:00AM  Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Regulatory Update on Pre-BLA Meeting for Vicinium® Business Wire +8.41%
May-21-19 07:00AM  Sesen Bio Announces Acceptance of Analytical Comparability Plan by the U.S. Food and Drug Administration to Support the BLA and Commercialization of Its Lead Asset, Vicinium® for Non-Muscle Invasive Bladder Cancer Business Wire +12.57%
May-20-19 11:26AM  Options Traders Expect Huge Moves in Sesen Bio (SESN) Stock Zacks +21.53%
May-13-19 07:00AM  Sesen Bio Reports First Quarter 2019 Financial Results and Updated, Preliminary Primary and Additional Secondary Endpoint Data from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer Business Wire
May-01-19 07:45AM  Will the Good News for Vicinium Continue for Sesen Bio, They Will Tell Investors Soon ACCESSWIRE
Apr-29-19 07:30AM  Sesen Bio to Host Conference Call to Review First Quarter 2019 Financial Results and Updated Preliminary Data from Phase 3 VISTA Trial Business Wire +12.73%
Mar-28-19 09:45AM  Four Healthcare Stocks Getting a Boost on Thursday ACCESSWIRE +6.64%
Mar-27-19 08:00AM  Positive Results and New Technology Give Rise to Antibody Dominance GlobeNewswire
Mar-09-19 10:09PM  Edited Transcript of SESN earnings conference call or presentation 4-Mar-19 1:00pm GMT Thomson Reuters StreetEvents
Mar-07-19 12:56PM  What Kind Of Shareholder Owns Most Sesen Bio, Inc. (NASDAQ:SESN) Stock? Simply Wall St.
Mar-04-19 07:30AM  Sesen Bio Reports Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial Business Wire -6.86%
Feb-25-19 04:20PM  Sesen Bio to Host Conference Call to Review Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial Business Wire
Jan-22-19 09:30AM  Health Stocks Benefitting the Most from Rally ACCESSWIRE
Jan-18-19 11:36AM  Sesen Bio, Inc. (NASDAQ:SESN): A Fundamentally Attractive Investment Simply Wall St.
Jan-03-19 06:30AM  Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer Business Wire -36.74%
Dec-27-18 12:45PM  4 Healthcare Stocks That Could Test December Highs ACCESSWIRE +6.50%
06:30AM  Sesen Bio to Host Conference Call to Review Updated VISTA Trial Data in Non-Muscle Invasive Bladder Cancer Business Wire
Dec-03-18 06:30AM  Sesen Bio Appoints Drug Development Expert, Dennis Kim, M.D., MPH, as Chief Medical Officer Business Wire
Nov-08-18 09:50AM  3 Health Care Stocks Seeing Heightened Activity After Midterms ACCESSWIRE +20.78%
06:30AM  Sesen Bio Reports Third Quarter 2018 Financial Results and Planned VISTA Trial Readouts Business Wire
Oct-15-18 08:40AM  Implied Volatility Surging for Sesen Bio (SESN) Stock Options Zacks
Sep-27-18 11:53AM  Do Institutions Own Shares In Sesen Bio Inc (NASDAQ:SESN)? Simply Wall St. +8.08%
Sep-20-18 08:27AM  Sesen Bio to Present Three-month VISTA Trial Data at Global Congress on Bladder Cancer 2018 Business Wire
Sep-05-18 11:45AM  Here's Why Momentum Investors Will Love Sesen Bio (SESN) Zacks
04:46AM  Sesen Bio (SESN) Continue to Surge Higher? Zacks
Aug-31-18 12:45PM  3 Cancer Treatment Stocks that Moved Higher in August ACCESSWIRE +9.27%
Aug-14-18 06:30AM  Sesen Bio Reports Second Quarter 2018 Financial Results and Pipeline Updates Business Wire
Aug-09-18 06:30AM  Sesen Bio Announces Vicinium Granted Fast Track Designation by FDA for Treatment of Non-Muscle Invasive Bladder Cancer Business Wire +12.34%
Aug-07-18 04:01PM  Sesen Bio Announces CEO and Board Transitions as Company Prepares for 12-Month VISTA Trial Data and Regulatory Submission in 2019 Business Wire
Aug-02-18 06:30AM  Sesen Bio to Present at the Canaccord Genuity 38th Annual Growth Conference Business Wire
Jul-27-18 07:55AM  Free Pre-Market Technical Pulse on Sesen Bio and Three More Biotech Stocks ACCESSWIRE -5.06%
Jun-20-18 07:50AM  Stock Performance Review on Sesen Bio and Three Other Biotech ACCESSWIRE
Jun-05-18 09:04AM  Sesen Bio (SESN) Sees Hammer Chart Pattern: Time to Buy? Zacks +6.06%
Jun-04-18 04:01PM  Sesen Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock Business Wire
May-30-18 09:22PM  Sesen Bio Announces Pricing of Public Offering of Common Stock Business Wire +9.09%
04:00PM  Sesen Bio Announces Proposed Public Offering of Common Stock Business Wire
May-29-18 06:30AM  Sesen Bio to Present at the Jefferies 2018 Global Healthcare Conference Business Wire -5.17%
May-21-18 02:15PM  Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ Patients Business Wire -23.00%
11:39AM  NasdaqGM Healthcare Industry: A Dive Into Sesen Bio Inc (NASDAQ:SESN) Simply Wall St.
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate, which is in Phase I/II clinical trials for use in the treatment of various types of EpCAM-positive solid tumors. It is also developing Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor that is in Phase I/IIa clinical trials for the treatment of squamous cell carcinoma of the head and neck. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.